Ipamorelin and CJC-1295 have been a regulatory mess for the last 18 months. In September 2024 the FDA pulled both off the Category 2 restricted list, but not by promoting them to Category 1 (compoundable). The original nominators just withdrew their nominations and the compounds dropped through the floor (FDA PCAC briefing document, 2024). That left a dead zone: not Category 2, not Category 1, no clear answer.
Then February 2026 happened. HHS Secretary RFK Jr. announced roughly 14 of the 19 previously Category 2 peptides are headed back to Category 1, which restores 503A compounding access with a script. Ipamorelin and CJC-1295 are on that list (Oath Peptides, 2026). Where we sit in April 2026: some compounding pharmacies are already filling, formal Category 1 confirmation is expected soon, and the path through a doctor and a USP <797> pharmacy is open again for most people.
Key Takeaways
- —Both ipamorelin and CJC-1295 came off FDA Category 2 in September 2024 and look set to land back in Category 1 (compoundable) under RFK Jr.'s February 2026 reclassification.
- —The clean access route is still a licensed physician's script through a USP <797>-compliant compounding pharmacy, not gray-market research peptide vendors.
- —Teichman et al. (2006) is the human data that matters: CJC-1295 pushed GH 2-10× and IGF-1 0.5-3× sustained for 9-11 days post-injection.
- —Compare ipa and CJC-1295 mechanisms and dosing with the Next Pep comparison tool before your first consultation.
The September 2024 removal made things weird for compounding pharmacies and prescribers. The compounds weren't explicitly green-lit (Category 1) and weren't explicitly banned (Category 2). Pharmacies split, some kept dispensing on the basis that the restriction was lifted, others paused waiting for clearer footing.
What the February 2026 announcement does in practice: PCAC (Pharmacy Compounding Advisory Committee) review is expected to formally drop these onto Category 1 before mid-2026. Until that lands, some pharmacies are compounding under the RFK announcement as guidance, others are waiting for the official listing. If you're trying to get a script filled now, ask the pharmacy directly which basis they're working from.
These two work on different receptors and almost nobody runs them solo, which is why they get sold and discussed together as a stack. Knowing what each one actually does still matters when you're verifying quality.
Ipamorelin is a pentapeptide GHRP (growth hormone releasing peptide) at MW 711.85 Da, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It hits GHS-R1a (the ghrelin receptor) in the pituitary. The selectivity is the headline: at 200× its effective dose it didn't significantly bump ACTH or cortisol in preclinical work, which no earlier GHRP managed (Raun et al., 1998). Half-life around 2 hours.
CJC-1295 (with or without DAC) is a 30-amino-acid GHRH analogue. The DAC (Drug Affinity Complex) version uses a lysine-maleimide conjugation that lets it bind albumin, stretching the half-life from minutes to 6-8 days. A single CJC-1295 DAC shot raised plasma GH 2-10× and IGF-1 0.5-3× for 9-11 days post-injection in the Teichman 2006 phase I/II human trial, the only real human evidence for this compound class (PubMed, Teichman et al., 2006).
Each compound has its own molecular fingerprint that mass spec on the COA needs to confirm.
For ipamorelin: Theoretical MW 711.85 Da. HPLC purity ≥98%. The COA should name ipamorelin (not a generic "GHRP") and show MW within ±0.5 Da. Because ipa's whole pitch is selectivity, any contaminant that's a structurally similar GHRP (GHRP-2, GHRP-6) screws up that profile, so purity matters here beyond just the percentage on the cert.
For CJC-1295 without DAC: Theoretical MW around 3,295 Da. Half-life is way shorter than the DAC form (minutes vs. days). This is the form you run ED, often timed around training or sleep, to produce discrete pulsatile GH releases.
For CJC-1295 with DAC: Theoretical MW around 3,368 Da. This is what Teichman studied, and it's why weekly dosing works: albumin binding stretches the half-life dramatically. The MW gap from the non-DAC form is small, but mass spec on the COA needs to confirm which one you've actually got, because the PK and dosing schedule are completely different.
Third-party tested is the same standard as any research peptide: named independent lab (Janoshik, Finnrick, or equivalent), verifiable report ID, lot-specific paperwork, current test date.
Even with the regulatory picture still moving, the clinical path for running CJC + ipa goes through a licensed prescriber and a compounding pharmacy. The prescriber side is where most protocols quietly fall apart.
Baseline lab work. At minimum, the script writer should be ordering IGF-1 (the primary readout, and what Teichman used as the main endpoint), fasting glucose and insulin (GH is counter-regulatory to insulin), and thyroid function (GH influences T4-T3 conversion). If a provider is writing scripts without baseline IGF-1, they can't actually tell you whether the protocol is doing anything.
They know the DAC vs. non-DAC distinction. CJC-1295 with DAC (weekly, 6-8 day half-life) and CJC-1295 without DAC (ED, half-life in minutes) produce completely different GH profiles. Teichman 2006 used the DAC form. A prescriber who blurs the two, or a pharmacy filling one when the script said the other, is a quality failure full stop.
Glucose monitoring. GH is counter-regulatory to insulin, so any GH pulse drops insulin sensitivity acutely. At ipa + CJC doses the effect is modest, but fasting glucose should still get rechecked periodically in anyone with existing glucose management concerns.
The ipamorelin research profile and the in-depth ipamorelin + CJC-1295 guide cover the dual-receptor pairing, the Teichman 2006 numbers, the 2024 Category 2 history, and full dosing tables. Read both before your prescriber consult and you'll be able to push back on clinical detail instead of just nodding through the provider's summary. The peptide library puts the whole GH secretagogue class, ipa, CJC-1295, sermorelin, and others, in structured citation-backed format in one spot.
If you want to put this stack against sermorelin, a simpler GHRH analogue with a longer approval history, the comparison tool lines all three up side by side. Once you've got a protocol, the dosing calculator handles reco for both compounds: enter your vial concentration and target dose, get exact draw volume in mL and syringe units back. Next Pep is the independent research reference, not a pharmacy, not a telehealth platform, not a vendor.
Where we are in April 2026: both came off FDA Category 2 in September 2024, and the RFK Jr. February 2026 announcement points to formal Category 1 (compoundable) listing soon. Some compounding pharmacies are filling now off the back of the Category 2 removal, others are waiting for the formal listing. Ask your pharmacy directly which basis they're working from. With a physician's script and a compliant pharmacy, access is open in most US states.
CJC-1295 with DAC (Drug Affinity Complex) carries a maleimide group that lets it covalently bind albumin, stretching the half-life to 6-8 days per shot. One weekly injection holds sustained GH elevation. CJC-1295 without DAC has a half-life of minutes, so it gets run ED to produce discrete pulsatile GH pulses, often timed around training or sleep. Teichman 2006 used the DAC form. The two have completely different dosing implications and the script has to specify which one.
Teichman 2006 showed sustained IGF-1 elevation within 9-11 days of a single CJC-1295 injection. For a standard protocol where the goal is IGF-1 optimisation, follow-up IGF-1 bloods at 8-12 weeks of consistent dosing give the cleanest read. IGF-1 has slow response kinetics, so single time-point measurements in the first few weeks aren't a reliable protocol indicator.
Running CJC + ipa is synergistic because they hit different receptor systems, GHRHR (growth hormone releasing hormone receptor) via CJC-1295 and GHS-R1a (ghrelin receptor) via ipamorelin. Dual receptor activation produces a bigger GH pulse than either alone. CJC-1295 solo gives you a sustained baseline GH bump; ipa adds the selective pulsatile component on top. Most published clinical protocols and the practitioner data run the combo, not CJC-1295 standalone.
This article is for research and educational purposes only. Ipamorelin and CJC-1295 require a licensed physician's prescription for legal compounding access. Regulatory status is evolving — verify current FDA Category 1/2 status before initiating any protocol. Consult a qualified healthcare professional before starting any growth hormone secretagogue protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.